Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy

Rossi, Luigi; Verrico, Monica; Tomao, Silverio; Ricci, Fábio; Fontana, Antonella; Spinelli, Gian Paolo; Colonna, Maria Antonietta; Vici, Patrizia; Tomao, Federica

doi:10.1007/s00280-019-03981-5

Cited by 19 publications

(13 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The change in HER2 expression following NAET is a novel finding. Crosstalk between the ER and HER2 pathways has been described, 27 and a change in ER/PR/HER2 expression following NACT has been well documented 28,29 . The precise mechanisms by which residual tumours change profile remain unknown.…”

Section: Discussionmentioning

confidence: 99%

Morphological and molecular changes following neoadjuvant endocrine therapy of oestrogen receptor‐positive breast cancer: implications for clinical practice

et al. 2021

View full text Add to dashboard Cite

Aims Neoadjuvant endocrine therapy (NAET) is used in the management of oestrogen receptor (ER)‐positive breast cancer. The optimal method for histological assessment of response and the effect of NAET on the tumour morphology, grade and molecular profile remain unclear. The aim of this study is to investigate the NAET effect on tumour type, grade and molecular profile by analysing a well‐characterised cohort of breast cancer samples in a single large UK tertiary referral centre, and to provide guidance on the pathological assessment of those lesions to inform adjuvant management and prognosis. Methods and results A single large‐institution cohort of 132 patients who received NAET over a 13‐year period was identified. Comprehensive clinical, histopathological and follow‐up data were collected. A detailed histological review of a subset with residual post‐treatment carcinoma was undertaken. Two carcinomas (both of the lobular type) achieved complete pathological response. Central scarring was seen in 49.3% of tumours post‐treatment. Significant changes in tumour type (41.6%), tumour grade (downgrading in one‐third of tumours), and progesterone receptor (PR) expression (22.3%), with a switch to PR‐negative status in 17.6% of cases, were observed. The last of these was associated with an absence of tumour‐infiltrating lymphocytes (P = 0.005). Ten per cent of cases showed a change in HER2 expression (P = 0.002). The median patient survival was 60 months, and downgrading of tumours was associated with better overall survival (P = 0.05). Conclusions We propose a histological method for assessment of residual carcinoma following NAET, and recommend repeat ER/PR/HER2 testing to inform management and prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Morphological and molecular changes following neoadjuvant endocrine therapy of oestrogen receptor‐positive breast cancer: implications for clinical practice

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Ki-67 is a cellular marker for proliferation and it is an excellent marker to determine the growth fraction of a given cell population (Rossi et al, 2020).Regarding endometrial carcinoma cases, Ki-67 expression was positive in 90 %. It was found that there was a significant relation between Ki-67 expression and the histopathologic types of studied cases of endometrial carcinoma.…”

Section: Discussionmentioning

confidence: 99%

OCT4, Ki-67 and VEGF as Prognostic Factors in Endometrial Carcinoma and Their Role in The Differentiation between Atypical Endometrial Hyperplasia and Grade 1 Endometrial Carcinoma: an Immunohistochemical study

El‐Anwar

Amer

2021

International Journal of Cancer and Biomedical Research

View full text Add to dashboard Cite

It is with great pleasure that I write this editorial to welcome you to the IJCBR. This journal provides a platform for publication of original and reviews research articles, short communications, letter to editor, thesis abstract, conference report, and case studies. These types of publication are directed at the interface of the fields of cancer and biomedical research.The IJCBR relies on a distinguished expert of the Advisory and Editorial Board Members from the top international league covering in depth the related topics. They timely review all manuscripts and maintain highest standards of quality and scientific methodology and ethical concepts. Meanwhile, we take all possible means to keep the time of the publication process as short as possible.I take this chance to welcome your contributions to the IJCBR and have every expectation that it will soon become one of the most respected journals in both the fields of cancer and biomedical research.

show abstract

“…However, there were no significant changes in the GR score before and after chemotherapy. This may also be due to intratumoral heterogeneity but in breast cancer patients, steroid hormone receptor profiles were also reported to be different between pre-and post-chemotherapy [34], and similar changes in GR may occur in ESCC patients but further investigations are required for clarification.…”

Section: Discussionmentioning

confidence: 99%

GR, Sgk1, and NDRG1 in esophageal squamous cell carcinoma: their correlation with therapeutic outcome of neoadjuvant chemotherapy

et al. 2020

View full text Add to dashboard Cite

Background: Esophageal squamous cell carcinoma (ESCC) is a highly malignant neoplasm. The glucocorticoid (GC)-glucocorticoid receptor (GR) pathway plays pivotal roles in cellular response to various stresses of tumor cells, including chemotherapy. However, the status of the GC-GR pathway in ESCC, including its correlation with chemotherapeutic responses, is largely unknown. Methods: GR, serum-and glucocorticoid-regulated kinase 1 (Sgk1), and N-myc down regulation gene 1 (NDRG1) were immunolocalized in 98 patients with ESCC who had undergone esophagectomy following neoadjuvant chemotherapy (NAC) with 2 courses of 5-fluorouracil + cisplatin. We also examined biopsy specimens before NAC in 42 cases and compared the results between those before and after NAC. Results: Overall survival (OS) of the patients treated with surgery following NAC was significantly shorter in the group with high GR than that with low GR status (P = 0.0473). Both OS and disease-free survival (DFS) were significantly shorter in both Sgk1-and NDRG1-high groups than in the low groups (OS: Sgk1, P = 0.0055; NDRG1, P = 0.0021; DFS: Sgk1, P = 0.0240; NDRG1, P = 0.0086). Biopsy specimens before NAC showed significantly shorter DFS in the high Sgk1 group (P = 0.0095), while both OS and DFS were shorter in the high NDRG1 group (OS, P = 0.0233; DFS, P = 0.0006) than in the respective low groups. In the high NDRG1 group of biopsy specimens before NAC, the tumor reduction rate by NAC was significantly attenuated (P = 0.021). Conclusions: High GR, Sgk1, and NDRG1 statuses in ESCC after NAC was significantly associated with an overall worse prognosis, with no significant changes in their expression levels before and after NAC. Therefore, increased activity of the GC-GR pathway with enhanced induction of Sgk1 and NDRG1 in carcinoma cells play pivotal roles in tumor progression and development of chemo-resistance in patients with ESCC undergoing NAC.

show abstract

Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy

Cited by 19 publications

References 42 publications

Morphological and molecular changes following neoadjuvant endocrine therapy of oestrogen receptor‐positive breast cancer: implications for clinical practice

Morphological and molecular changes following neoadjuvant endocrine therapy of oestrogen receptor‐positive breast cancer: implications for clinical practice

OCT4, Ki-67 and VEGF as Prognostic Factors in Endometrial Carcinoma and Their Role in The Differentiation between Atypical Endometrial Hyperplasia and Grade 1 Endometrial Carcinoma: an Immunohistochemical study

GR, Sgk1, and NDRG1 in esophageal squamous cell carcinoma: their correlation with therapeutic outcome of neoadjuvant chemotherapy

Contact Info

Product

Resources

About